The FDA’s expert panel on testosterone labeling revisions, influenced by the 2023 TRAVERSE study, signals evidence-based regulatory shifts that could…
labeling
1 post
The FDA’s expert panel on testosterone labeling revisions, influenced by the 2023 TRAVERSE study, signals evidence-based regulatory shifts that could…